布朗大学领导的一项研究发现，接种重组带状疱疹疫苗Shingrix的老年人，在四年内被诊断为痴呆症的风险降低了24%1。该研究由布朗大学公共卫生学院助理教授Kaley Hayes主导，相关成果于2026年8月25日发表在《内科学年鉴》2026年第179卷第7期第958页1。
研究团队分析了2017年至2022年间全美超过5,500家专业护理机构的医疗保险数据，共纳入509,926名66岁及以上入住该机构的老年人1。在这些参与者中，仅有8,843人接种了带状疱疹疫苗1。数据显示，接种疫苗的参与者中有18.8%发展为痴呆症，而未接种者的比例为24.6%1。研究人员估计，大约每17名接种该疫苗的人中可预防1例痴呆症的发生1。尽管研究作者强调该研究不能证明因果关系，但提示疫苗可能具有神经保护益处1。
A study led by Brown University has found that older adults who received the recombinant shingles vaccine Shingrix had a 24% lower risk of being diagnosed with dementia over a four-year period 1. The research was authored by Kaley Hayes, an assistant professor at the Brown University School of Public Health, and published in the Annals of Internal Medicine (2026, 179(7): 958) on August 25, 2026 1.
The analysis utilized Medicare data from 509,926 adults aged 66 and older residing in over 5,500 professional nursing facilities across the United States between 2017 and 2022 1. Among these participants, only 8,843 had received the shingles vaccine 1. Of those vaccinated, 18.8% developed dementia, compared to 24.6% of the unvaccinated participants 1. Researchers estimated that approximately one case of dementia could be prevented for every 17 people vaccinated 1. Although the study cannot establish a causal relationship, the findings indicate that the vaccine may provide neuroprotective benefits 1.
评论
还没有评论，欢迎留下第一条。